Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of repeated Bimatoprost SR versus timolol in open-angle glaucoma or ocular hypertension
NL-OMON45083Phase 3Withdrawn
- Sponsor
- Allergan
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Allergan. Primary endpoints: Intraocular pressure, Adverse events and 5 more. Planned start Mar 2015; status: withdrawn.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NL-OMON45083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45083.